Prestige Consumer Healthcare's stock experienced a 24-hour plunge of 7.14% in recent trading, reflecting significant investor disappointment following the company's latest financial results.

The sharp decline comes after the consumer healthcare firm reported fiscal fourth-quarter revenue and adjusted earnings per share that fell short of analyst expectations. Revenue for the quarter dropped 5% year-over-year to $281.6 million, missing the consensus estimate of $293.7 million, while adjusted EPS of $1.23 missed the $1.39 estimate. The company cited several operational challenges including supply constraints in its Eye & Ear Care category that limited ability to meet demand for Clear Eyes products, shipping disruptions in the Middle East affecting international segment revenue, and unfavorable order timing comparisons with the prior year.

Adding to investor concerns, Prestige provided fiscal 2027 guidance that also disappointed the market. The company forecast revenue of $1.1 billion to $1.12 billion and adjusted diluted EPS of $4.42 to $4.51, both below analyst expectations of $1.16 billion in revenue and $4.79 in EPS. While the company announced an agreement to acquire Australian therapeutic skincare company LaCorium Health for approximately $150 million, this strategic move was overshadowed by the weak financial performance and outlook.